Sign In
Buy MEDP
$450.82
+5.23 (+1.17%)
At Close: Jun 03, 2026
Here is Why Growth Investors Should Buy Medpace (MEDP) Now
01:46pm, Friday, 19'th May 2023
Medpace (MEDP) possesses solid growth attributes, which could help it handily outperform the market.
Medpace: Gaining Market Share While Others Struggle
02:22pm, Monday, 08'th May 2023
Medpace is one the largest Clinical Research Organisations in the market, and consistently winning market share. On April 24, Medpace presented its earnings for the first quarter of FY23, showing oper
Medpace Holdings Crushed Analyst Expectations
08:00am, Saturday, 06'th May 2023
We've got a look at this company, what's going on with Pepsi, and other market news.
3 Reasons Why Growth Investors Shouldn't Overlook Medpace (MEDP)
02:27pm, Wednesday, 03'rd May 2023
Medpace (MEDP) is well positioned to outperform the market, as it exhibits above-average growth in financials.
New Strong Buy Stocks for May 3rd
09:07am, Wednesday, 03'rd May 2023
COCO, RYI, GTX, MEDP and SKX have been added to the Zacks Rank #1 (Strong Buy) List on May 3rd, 2023.
Why MTY Food Group Is Worth a Look
07:00am, Saturday, 29'th Apr 2023
You might be familiar with some of the brands, but the company's name is probably not on your radar.
All You Need to Know About Medpace (MEDP) Rating Upgrade to Strong Buy
01:42pm, Thursday, 27'th Apr 2023
Medpace (MEDP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Medpace (MEDP) Beats Q1 Earnings and Revenue Estimates
06:59pm, Monday, 24'th Apr 2023
Medpace (MEDP) came out with quarterly earnings of $2.27 per share, beating the Zacks Consensus Estimate of $1.76 per share. This compares to earnings of $1.69 per share a year ago.
Medpace, A Top 1% Earnings Stock, Just Crushed Expectations — Here's A Key Measure To Watch
05:50pm, Monday, 24'th Apr 2023
Medpace easily beat Wall Street's first-quarter projections late Monday and boosted its full-year outlook. In response, MEDP stock rocketed.
Medpace Holdings: Promising CRO With Strong Growth And Excellent Fundamentals
03:21am, Tuesday, 11'th Apr 2023
Strong financial growth in 2022, with healthy key performance metrics. Risks are contract cancellations, drug development unpredictability, and industry consolidation.
Medpace Holdings: Priced With High Expectations
08:44am, Saturday, 01'st Apr 2023
Cincinnati-based Medpace provides the biotechnology world with Phase 1-IV clinical development services using scientifically driven research. MEDP hit record Q4 2022 revenue of $394.1 million, indicat
Medpace Holdings, Inc. to Report First Quarter 2023 Financial Results on April 24, 2023
04:05pm, Tuesday, 28'th Mar 2023
CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced that it will report its first quarter 2023 financial results after the market close on Monday, April
Want $1 Million in Retirement? Invest $200,000 in These 3 Stocks and Wait a Decade
08:45am, Saturday, 11'th Mar 2023
Doximity's ability to connect physicians with pharmaceuticals and health systems is a wildly prosperous pairing. Medpace's customers could struggle in 2023, but its long-term opportunity will only gro
Medpace Holdings, Inc. (MEDP) Q4 2022 Earnings Call Transcript
01:06pm, Tuesday, 14'th Feb 2023
Medpace Holdings, Inc. (NASDAQ:MEDP ) Q4 2022 Earnings Conference Call February 14, 2023 9:00 AM ET Company Participants Lauren Morris - IR August Troendle - CEO Jesse Geiger - President Kevin Brady -
InMode Jumps Despite Mixed 2023 Outlook, But Uncertainty Continues For Medpace
10:14am, Tuesday, 14'th Feb 2023
InMode issued a mixed outlook Tuesday, but INMD stock jumped as fellow medtech Medpace slumped on 2023 uncertainty. The post InMode Jumps Despite Mixed 2023 Outlook, But Uncertainty Continues For Medp
